The Experts below are selected from a list of 1128 Experts worldwide ranked by ideXlab platform

Masafumi Fukushima - One of the best experts on this subject based on the ideXlab platform.

Hirotoshi Morii - One of the best experts on this subject based on the ideXlab platform.

C. Frederic Strife - One of the best experts on this subject based on the ideXlab platform.

  • A prospective double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus Dihydrotachysterol
    The Journal of pediatrics, 1994
    Co-Authors: James C.m. Chan, Paul T. Mcenery, Vernon M. Chinchilli, Carolyn Abitbol, Frank G. Boineau, Aaron L. Friedman, Gary M. Lum, Shane Roy, Edward J. Ruley, C. Frederic Strife
    Abstract:

    Because controlled trials in adults have shown accelerated deterioration of renal function in a small number of patients receiving calcitriol for renal osteodystrophy, we initiated a prospective, randomized, double-blind study of the use of calcitriol versus Dihydrotachysterol in children with chronic renal insufficiency. We studied children aged 1½ through 10 years, with a calculated glomerular filtration rate between 20 and 75 ml/min per 1.73 m 2 , and with elevated serum parathyroid hormone concentrations. Ninety-four patients completed a mean of 8.0 months of control observations and were randomly assigned to a treatment period; 82 completed the treatment period of at least 6 months while receiving a calcitriol dosage (mean±SD) of 17.1±5.9 ng/kg per day or a Dihydrotachysterol dosage of 13.8±3.3 μg/kg per day. With treatment the height z scores for both calcitriol- and Dihydrotachysterol-treated groups showed no differences between the two groups. In relation to cumulative dose, there was a significant decrease in glomerular filtration rate for both calcitriol and Dihydrotachysterol; for calcitriol the rate of decline was significantly steeper ( p =0.0026). The treatment groups did not differ significantly with respect to the incidence of hypercalcemia (serum calcium concentration >2.7 mmol/L (>11 mg/dl)). We conclude that careful follow-up of renal function is mandatory during the use of either calcitriol or Dihydrotachysterol because both agents were associated with significant declines in renal function. There was no significant difference between calcitriol and Dihydrotachysterol in promoting linear growth or causing hypercalcemia in children with chronic renal insufficiency. Dihydrotachysterol, the less costly agent, can be used with equal efficacy.

James C.m. Chan - One of the best experts on this subject based on the ideXlab platform.

  • Comparison of the biological effectiveness of calcitriol and Dihydrotachysterol
    Nutrition Research, 1995
    Co-Authors: Mary Jacob, Faith S. Boyle, Tatiana T Antonovych, James C.m. Chan
    Abstract:

    Calcitriol and Dihydrotachysterol are both used in clinical practice as treatment for several renal and endocrine conditions. However, despite their routine use, therapeutic dosages and concomitant adverse effects of these medications have yet to be clarified. In our study, a low, high and extreme dosage of calcitriol (20, 60, 120 ng/kg/day) or Dihydrotachysterol (15, 45, 90 μg/kg/day) was administered to six groups of male Sprague Dawley rats for four weeks. The seventh group served as untreated controls. Our results indicated no difference in food intake, weight gain, or total or ionized plasma calcium among treatment groups. Rats receiving 90 μg/kg/day Dihydrotachysterol excreted more calcium than those receiving 120 ng/kg/day calcitriol (p < 0.002). Femur and kidney calcium showed no significant differences for any dosages used of either medication. Mean urine calcium was significantly correlated with ionized plasma calcium (p < 0.006) and kidney calcium (p < 0.02). Light microscopy revealed evidence of calcification in one rat out of six receiving the extreme dose (120 ng/kg/day) of calcitriol and one rat out of six receiving the extreme dose (90 μg/kg/day) of Dihydrotachysterol. These results suggest that serum and urine calcium must be carefully monitored during either form of vitamin D therapy, but no effect on calcium content or histology of the kidneys was observed in the common therapeutic range.

  • A prospective double-blind study of growth failure in children with chronic renal insufficiency and the effectiveness of treatment with calcitriol versus Dihydrotachysterol
    The Journal of pediatrics, 1994
    Co-Authors: James C.m. Chan, Paul T. Mcenery, Vernon M. Chinchilli, Carolyn Abitbol, Frank G. Boineau, Aaron L. Friedman, Gary M. Lum, Shane Roy, Edward J. Ruley, C. Frederic Strife
    Abstract:

    Because controlled trials in adults have shown accelerated deterioration of renal function in a small number of patients receiving calcitriol for renal osteodystrophy, we initiated a prospective, randomized, double-blind study of the use of calcitriol versus Dihydrotachysterol in children with chronic renal insufficiency. We studied children aged 1½ through 10 years, with a calculated glomerular filtration rate between 20 and 75 ml/min per 1.73 m 2 , and with elevated serum parathyroid hormone concentrations. Ninety-four patients completed a mean of 8.0 months of control observations and were randomly assigned to a treatment period; 82 completed the treatment period of at least 6 months while receiving a calcitriol dosage (mean±SD) of 17.1±5.9 ng/kg per day or a Dihydrotachysterol dosage of 13.8±3.3 μg/kg per day. With treatment the height z scores for both calcitriol- and Dihydrotachysterol-treated groups showed no differences between the two groups. In relation to cumulative dose, there was a significant decrease in glomerular filtration rate for both calcitriol and Dihydrotachysterol; for calcitriol the rate of decline was significantly steeper ( p =0.0026). The treatment groups did not differ significantly with respect to the incidence of hypercalcemia (serum calcium concentration >2.7 mmol/L (>11 mg/dl)). We conclude that careful follow-up of renal function is mandatory during the use of either calcitriol or Dihydrotachysterol because both agents were associated with significant declines in renal function. There was no significant difference between calcitriol and Dihydrotachysterol in promoting linear growth or causing hypercalcemia in children with chronic renal insufficiency. Dihydrotachysterol, the less costly agent, can be used with equal efficacy.

Morita A - One of the best experts on this subject based on the ideXlab platform.